View from City Road: World will keep taking the tablets
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.The flurry of interest in drug shares yesterday was due to the approval of Tagamet, the ulcer treatment, for over-the-counter sales. The more drugs go off prescription, the larger the offset to any squeeze on margins from cost-conscious governments. It is likely, though, that worries about the impact of the Clinton healthcare reforms have anyway been overdone. The World Bank's world development report, which focuses on health this year, provides some support for the view that the industry's growth is unlikely to slow.
World spending on health totalled about dollars 1,700bn in 1990, or 8 per cent of global income. The share of national income going on health tends to rise as countries get richer, so that the health industry grows steadily faster than the economy as a whole. The potential market for drugs in rapidly growing Third World countries is enormous: China's spending of dollars 7 a year per head on drugs compares with Britain's dollars 97.
True, the World Bank shows that much of that spending - whether public or private - is inefficient. Glamour medicine still triumphs over more effective preventative measures. But the underlying demand for health care is still so strong, and is so far from the point of diminishing returns in Third World markets, that the industry's strengths should not be overlooked.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments